Clinical impact of sample interference on intensive insulin therapy in severely burned patients: A pilot study

Nam Tran, Zachary R. Godwin, Jennifer C. Bockhold, Anthony G. Passerini, Julian Cheng, Morgan Ingemason

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Severely burned patients benefit from intensive insulin therapy (IIT) for tight glycemic control (TGC). The authors evaluated the clinical impact of automatic correction of hematocrit and ascorbic acid interference for bedside glucose monitoring performance in critically ill burn patients. The performance of two point-of-care glucose monitoring systems (GMSs): 1) GMS1, an autocorrecting device, and 2) GMS2, a noncorrecting device were compared. Sixty remnant arterial blood samples were collected in a prospective observational study to evaluate hematocrit and ascorbic acid effects on GMS1 vs GMS2 accuracy paired against a plasma glucose reference. Next, we enrolled 12 patients in a pilot randomized controlled trial. Patients were randomized 1:1 to receive IIT targeting a TGC interval of 111 to 151 mg/dl and guided by either GMS1 or GMS2. GMS bias, mean insulin rate, and glycemic variability were calculated. In the prospective study, GMS1 results were similar to plasma glucose results (mean bias, -0.75 [4.0] mg/dl; n = 60; P =.214). GMS2 results significantly differed from paired plasma glucose results (mean bias, -5.66 [18.7] mg/dl; n = 60; P =.048). Ascorbic acid therapy elicited significant GMS2 performance bias (29.2 [27.2]; P <.001). Randomized controlled trial results reported lower mean bias (P <.001), glycemic variability (P <.05), mean insulin rate (P <.001), and frequency of hypoglycemia (P <.001) in the GMS1 group than in the GMS2 group. Anemia and high-dose ascorbic acid therapy negatively impact GMS accuracy and TGC in burn patients. Automatic correction of confounding factors improves glycemic control. Further studies are warranted to determine outcomes associated with accurate glucose monitoring during IIT.

Original languageEnglish (US)
Pages (from-to)72-79
Number of pages8
JournalJournal of Burn Care and Research
Volume35
Issue number1
DOIs
StatePublished - 2014

Fingerprint

Insulin
Glucose
Ascorbic Acid
Therapeutics
Hematocrit
Randomized Controlled Trials
Point-of-Care Systems
Prospective Studies
Equipment and Supplies
Hypoglycemia
Critical Illness
Observational Studies
Anemia

ASJC Scopus subject areas

  • Emergency Medicine
  • Rehabilitation
  • Surgery

Cite this

Clinical impact of sample interference on intensive insulin therapy in severely burned patients : A pilot study. / Tran, Nam; Godwin, Zachary R.; Bockhold, Jennifer C.; Passerini, Anthony G.; Cheng, Julian; Ingemason, Morgan.

In: Journal of Burn Care and Research, Vol. 35, No. 1, 2014, p. 72-79.

Research output: Contribution to journalArticle

Tran, Nam ; Godwin, Zachary R. ; Bockhold, Jennifer C. ; Passerini, Anthony G. ; Cheng, Julian ; Ingemason, Morgan. / Clinical impact of sample interference on intensive insulin therapy in severely burned patients : A pilot study. In: Journal of Burn Care and Research. 2014 ; Vol. 35, No. 1. pp. 72-79.
@article{4f56923eb1e347a499a3b9967851a7f6,
title = "Clinical impact of sample interference on intensive insulin therapy in severely burned patients: A pilot study",
abstract = "Severely burned patients benefit from intensive insulin therapy (IIT) for tight glycemic control (TGC). The authors evaluated the clinical impact of automatic correction of hematocrit and ascorbic acid interference for bedside glucose monitoring performance in critically ill burn patients. The performance of two point-of-care glucose monitoring systems (GMSs): 1) GMS1, an autocorrecting device, and 2) GMS2, a noncorrecting device were compared. Sixty remnant arterial blood samples were collected in a prospective observational study to evaluate hematocrit and ascorbic acid effects on GMS1 vs GMS2 accuracy paired against a plasma glucose reference. Next, we enrolled 12 patients in a pilot randomized controlled trial. Patients were randomized 1:1 to receive IIT targeting a TGC interval of 111 to 151 mg/dl and guided by either GMS1 or GMS2. GMS bias, mean insulin rate, and glycemic variability were calculated. In the prospective study, GMS1 results were similar to plasma glucose results (mean bias, -0.75 [4.0] mg/dl; n = 60; P =.214). GMS2 results significantly differed from paired plasma glucose results (mean bias, -5.66 [18.7] mg/dl; n = 60; P =.048). Ascorbic acid therapy elicited significant GMS2 performance bias (29.2 [27.2]; P <.001). Randomized controlled trial results reported lower mean bias (P <.001), glycemic variability (P <.05), mean insulin rate (P <.001), and frequency of hypoglycemia (P <.001) in the GMS1 group than in the GMS2 group. Anemia and high-dose ascorbic acid therapy negatively impact GMS accuracy and TGC in burn patients. Automatic correction of confounding factors improves glycemic control. Further studies are warranted to determine outcomes associated with accurate glucose monitoring during IIT.",
author = "Nam Tran and Godwin, {Zachary R.} and Bockhold, {Jennifer C.} and Passerini, {Anthony G.} and Julian Cheng and Morgan Ingemason",
year = "2014",
doi = "10.1097/BCR.0b013e31829b3700",
language = "English (US)",
volume = "35",
pages = "72--79",
journal = "Journal of Burn Care and Research",
issn = "1559-047X",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Clinical impact of sample interference on intensive insulin therapy in severely burned patients

T2 - A pilot study

AU - Tran, Nam

AU - Godwin, Zachary R.

AU - Bockhold, Jennifer C.

AU - Passerini, Anthony G.

AU - Cheng, Julian

AU - Ingemason, Morgan

PY - 2014

Y1 - 2014

N2 - Severely burned patients benefit from intensive insulin therapy (IIT) for tight glycemic control (TGC). The authors evaluated the clinical impact of automatic correction of hematocrit and ascorbic acid interference for bedside glucose monitoring performance in critically ill burn patients. The performance of two point-of-care glucose monitoring systems (GMSs): 1) GMS1, an autocorrecting device, and 2) GMS2, a noncorrecting device were compared. Sixty remnant arterial blood samples were collected in a prospective observational study to evaluate hematocrit and ascorbic acid effects on GMS1 vs GMS2 accuracy paired against a plasma glucose reference. Next, we enrolled 12 patients in a pilot randomized controlled trial. Patients were randomized 1:1 to receive IIT targeting a TGC interval of 111 to 151 mg/dl and guided by either GMS1 or GMS2. GMS bias, mean insulin rate, and glycemic variability were calculated. In the prospective study, GMS1 results were similar to plasma glucose results (mean bias, -0.75 [4.0] mg/dl; n = 60; P =.214). GMS2 results significantly differed from paired plasma glucose results (mean bias, -5.66 [18.7] mg/dl; n = 60; P =.048). Ascorbic acid therapy elicited significant GMS2 performance bias (29.2 [27.2]; P <.001). Randomized controlled trial results reported lower mean bias (P <.001), glycemic variability (P <.05), mean insulin rate (P <.001), and frequency of hypoglycemia (P <.001) in the GMS1 group than in the GMS2 group. Anemia and high-dose ascorbic acid therapy negatively impact GMS accuracy and TGC in burn patients. Automatic correction of confounding factors improves glycemic control. Further studies are warranted to determine outcomes associated with accurate glucose monitoring during IIT.

AB - Severely burned patients benefit from intensive insulin therapy (IIT) for tight glycemic control (TGC). The authors evaluated the clinical impact of automatic correction of hematocrit and ascorbic acid interference for bedside glucose monitoring performance in critically ill burn patients. The performance of two point-of-care glucose monitoring systems (GMSs): 1) GMS1, an autocorrecting device, and 2) GMS2, a noncorrecting device were compared. Sixty remnant arterial blood samples were collected in a prospective observational study to evaluate hematocrit and ascorbic acid effects on GMS1 vs GMS2 accuracy paired against a plasma glucose reference. Next, we enrolled 12 patients in a pilot randomized controlled trial. Patients were randomized 1:1 to receive IIT targeting a TGC interval of 111 to 151 mg/dl and guided by either GMS1 or GMS2. GMS bias, mean insulin rate, and glycemic variability were calculated. In the prospective study, GMS1 results were similar to plasma glucose results (mean bias, -0.75 [4.0] mg/dl; n = 60; P =.214). GMS2 results significantly differed from paired plasma glucose results (mean bias, -5.66 [18.7] mg/dl; n = 60; P =.048). Ascorbic acid therapy elicited significant GMS2 performance bias (29.2 [27.2]; P <.001). Randomized controlled trial results reported lower mean bias (P <.001), glycemic variability (P <.05), mean insulin rate (P <.001), and frequency of hypoglycemia (P <.001) in the GMS1 group than in the GMS2 group. Anemia and high-dose ascorbic acid therapy negatively impact GMS accuracy and TGC in burn patients. Automatic correction of confounding factors improves glycemic control. Further studies are warranted to determine outcomes associated with accurate glucose monitoring during IIT.

UR - http://www.scopus.com/inward/record.url?scp=84892833088&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892833088&partnerID=8YFLogxK

U2 - 10.1097/BCR.0b013e31829b3700

DO - 10.1097/BCR.0b013e31829b3700

M3 - Article

C2 - 23884048

AN - SCOPUS:84892833088

VL - 35

SP - 72

EP - 79

JO - Journal of Burn Care and Research

JF - Journal of Burn Care and Research

SN - 1559-047X

IS - 1

ER -